Approval · Notice of Compliance 22960 · 2019
EVEROLIMUS: Notice of Compliance 22960
Issued October 18, 2019
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 22960
- Date
- October 18, 2019
- Company
- Novartis Pharmaceuticals Canada Inc.Montreal, Quebec, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- New Drug Submission (NDS)
- Submission class
- Labelling Only
- Reason
- Additional product name
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| EVEROLIMUS | 02492911 | Marketed |
| EVEROLIMUS | 02492938 | Marketed |
| EVEROLIMUS | 02492946 | Marketed |
Medicinal ingredients
- EVEROLIMUS 2.5 MG per TAB
- EVEROLIMUS 5 MG per TAB
- EVEROLIMUS 10 MG per TAB